| ||||
News, Publications, and Related Stories
Medical Edge Newspaper Dear Mayo Clinic: Please let me know if it would be safe to undergo prostate cancer surgery with a low platelet count (111,000) and if there is anything that can be done to avoid complications of the surgery. View Related 
Medical Edge Newspaper Dear Mayo Clinic: Please let me know if it would be safe to undergo prostate cancer surgery with a low platelet count (111,000) and if there is anything that can be done to avoid complications of the surgery. View Related 
Medical Edge Newspaper Dear Mayo Clinic: I have had a PSA of 1.2 for many years. Now a year later my PSA is 2.1. Should I be concerned and check further? I am 67 years old. View Related
Japan Herald -- April 8, 2010 Co-investigator, Jeremiah J. Morrissey, PhD,on a study to identify proteins secreted in urine that appear to accurately reveal the presence of about 90 percent of all kidney cancers. View Related 
Discovery's Edge -- Mayo Clinic's Research Publication Roughly 11 percent of those diagnosed have aggressive strains that are often discovered too late, rendering them inoperable. A search that began six years ago for biomarkers of those aggressive types is nearing conclusion. View Related 
Medical Edge Newspaper Dear Mayo Clinic: Does Mayo have advice for preventive measures men can take for prostate health? View Related 
U.S. News & World Report -- Mar. 3, 2010 Dr. R. Jeffrey Karnes talks about prostate screening guidelines. View Related 
The study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer. Additional audio and video resources are available on the Mayo Clinic News Blog. View Related 
Medical Edge Newspaper I was recently diagnosed with BPH. At what point would you recommend treatment? What are my treatment options? View Related 
Researchers say the findings from Mayo Clinic's campuses in Florida and Minnesota suggest that patients and their physicians should not overly worry about toxicity and side effects from the treatment, known as salvage external beam radiotherapy. View Related 
Publication: The Journal of Clinical Investigation -- September 2009 
Offering cancer patients in Florida and the Southeast access to investigational therapies through rigorously monitored clinical trials "The cancer field is rapidly moving to use of these new agents as a way to improve upon the success we have seen with more traditional therapies, such as chemotherapy and radiation," says says Michael Menefee, M.D., who heads the Phase I Clinical Trial Program in Oncology at Mayo Clinic, Jacksonville. View Related 
Mayo Clinic Cancer Center receives an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center. 
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases
Publication: Clinical Cancer Research -- Mar. 15, 2009 View Related 
Mayo Clinic Health Letter -- January 2009 Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. View Related
William C. Rupp, M.D., has been appointed CEO for the Florida campus effective Nov. 21, Mayo Clinic announced today. Rupp currently leads quality projects for Luther Midelfort, part of Mayo Health System, as well as Mayo Clinic. 
Patient Story -- Mike Carlson Prostate cancer treatment puts Mike Carlson on the right path. View Related 
Patient Story -- Dr. Randall Minion Diagnosed with prostate cancer at a relatively young age, Dr. Randall Minion chose robotic surgery as the best way to maintain his full, active lifestyle. View Related
Patient Story -- Jack Keller A thorough search for prostate cancer proved to be the right approach for Jack Keller. View Related 
Mouse study shows dopamine blocks tumor-feeding blood vessels "Sometimes new drugs may not be the answer. We looked instead at a novel use for an established product and have found very promising results," says Mayo Clinic oncology researcher Sujit Basu, M.D., Ph.D. View Related
Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related 
Research into the B7 molecules has been a "family affair" at Mayo. Many Mayo immunologists have joined together to tackle various aspects of their function and behavior and have discovered how they function.
Mayo Clinic Cancer Center had researchers from many disciplines presenting more than 60 oral abstracts and dozens of posters, also educational sessions and other special events throughout the 2007 ASCO program, June 1-5. View Related 
The National Institutes of Health chose Mayo Clinic as one of the first 12 institutions to receive Clinical and Translational Science Awards (CTSA) in October 2006. "There are two objects in medical education: to heal the sick and advance the science." - Dr. Charles H. Mayo 
Yuan-Ping Pang, Ph.D. established the Computer-Aided Molecular Design Laboratory (CAMDL) to learn more about how biological systems function and to establish models that could lead to new treatments for infectious diseases and cancer. View Related 
Osteoporosis was not even considered a disease before Mayo Clinic's 1980s groundbreaking epidemiology studies. Funded by a $1.2 million per year NIH Program Project grant, the osteoporosis research team is also taking their research to the genetic and molecular levels to study the physiology of bone metabolism in an aging population. Their studies investigate the TGF-beta-Inducible Early Gene (TIEG) gene's role in bone and skeletal disorders such as osteoporosis and breast cancer metastasis to the bone. View Related 
The Clinical Research Training Program provides a formal education in all aspects of clinical research, including grant-writing, legal and ethical issues, statistics, epidemiology and study design and protocols. "I realized how exciting research can be, and how exciting it is to advance the science." Jon Ebbert, M.D. View Related
In helping young investigators, Mayo Clinic again is connecting all the dots -- leading back to the same point, the same mission, ongoing and yet unchanged for over a century: the needs of the patient come first. New, young investigators are critical to biomedical research. Their fresh ideas, innovativeness, and enthusiasm are necessary for scientific progress. Yet the steps from a junior research position toward a self-sufficient laboratory can be difficult. Mayo Clinic is dedicated to fostering future, investigators. Here we look at two of them and what Mayo is doing to help. View Related 
Publication: Cancer -- June 15, 2006 The current results confirmed that there were changes in the prevalence of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. A chronological change in pathologic grading classification is suggested by evolving prognostic implications, which must be accounted for when comparing outcomes from different eras. View Related 
The invention of a novel imaging biotechnology called vibro-acoustography was reported in 1998, a fruit that matured from a mind dedicated to a deeper understanding of the mathematical and physical concepts that produce clear images of internal anatomy. James Greenleaf, Ph.D., a Mayo Clinic scientist and director of the Ultrasound Research Laboratory, is praised by the scientific community as one of the most creative scientists in ultrasonic biomedical imaging science. This article explores his contributions—novel ultrasound treatments, and biotechnology that produces clear images, some in 3D, of tiny structures deep within the body. View Related 
Medical Edge Television Doctors are using robots for many operations including prostate cancer surgery. Learn the latest on how this advance in technology is helping some patients get better faster. 
Publication: Journal of Clinical Oncology -- June 15, 2004 North Central Cancer Treatment Group with National Cancer Institute of Canada View Related
|
LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE
Use of this site signifies your agreement to the terms of use.
© 2012 Mayo Foundation for Medical Education and Research. All rights reserved.
